While MBI is linked to previously established amyloid‐beta (Aβ) and tau biomarkers, its association with plasma p‐tau217, a promising blood‐based biomarker for Alzheimer's disease (AD), remains unexplored. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.